Can MRI of the Prostate Combined With a Radiomics Evaluation Determine the Invasive Capacity of a Tumour
- Conditions
- Prostate Cancer
- Registration Number
- NCT05024162
- Lead Sponsor
- Nova Scotia Health Authority
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- Not specified
Inclusion Criteria:<br><br>An appropriate diagnostic MRI-P, defined as:<br><br> - Being performed on 3T MRI at the Halifax Infirmary Building<br><br> - Taken place within 5 weeks of study enrolment<br><br> - Having a detectable nodule which anatomically localizes to prostate cancer (PCa)<br> identified in diagnostic biopsy specimen<br><br> - Acquired T1+contrast, T2, and attenuated diffusion coefficient (ADC) series axial<br> images of the prostate<br><br>An appropriate diagnostic biopsy, defined as:<br><br> - Taken place within 2 months of the participant's MRI-P 1<br><br> - Taken place within 3 months of participant's study enrolment<br><br> - Reports diagnosis of PCa<br><br> - Reports a systematic assessment of the biopsy, assessing at least 12 cores<br><br> - Reports at least on core involved with PCa and this core must anatomically localise<br> to a nodule seen on MRI-P 1<br><br>Exclusion Criteria:<br><br> - Past prostatic interventions which would influence the prostate's structure<br><br> - Alterations to physiological testosterone levels<br><br> - Inability to position one's self in a reproducible fashion for an MRI-P<br><br> - Patient factors reported to produce significant artifact on MRI-P 1
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MRT Classification Change;MRT Classification: Baseline;MRT Classification: Week 8
- Secondary Outcome Measures
Name Time Method Model optmization with novel radiomic features and clinical covariates